22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › VIRIDIAN THERAPEUTICS INC. › 2024-2025

VIRIDIAN THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and VIRIDIAN THERAPEUTICS INC.’s Form 8-K, filed June 24, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 203Asset managers, any item
  • 1,563Fund votes
  • June 20, 2025Meeting date

Results at a glance

Meeting of June 20, 2025: 7 items on VIRIDIAN THERAPEUTICS INC.’s Form 8-K, filed June 24, 2025: 3 elected · 4 passed (calculated).

Dissent

Significant dissent: 1 director (23.2% against); 1 equity or compensation plan (49.8% against).

Notable dissent: 1 say-on-pay vote (77.8% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Caligan Partners (13F, 1.9%, as of September 30, 2026) · Tang Capital (13F, 1.6%, as of September 30, 2026)

Explore VIRIDIAN THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by VIRIDIAN THERAPEUTICS INC.

These tallies are VIRIDIAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VIRIDIAN THERAPEUTICS INC. — official shareholder meeting results, meeting held June 20, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jeff Ajer 71,946,644---- 95,5884,619,287 99.9%Elected—
Elect Director: Chris Cain, Ph.D. 68,841,891---- 3,200,3414,619,287 96%Elected—
Elect Director: Sarah Gheuens, M.D., Ph.D. 55,346,802---- 16,695,4304,619,287 77%Elected—
2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 76,059,006577,13925,374 ---- 99.2%Passed (calculated)—
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers 56,046,36615,957,52638,340 --4,619,287 78%Passed (calculated)—
4. Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 shares 35,322,72535,076,9021,642,605 --4,619,287 50.2%Passed (calculated)—
5. Approval of the Viridian Therapeutics, Inc 72,005,89625,66810,668 --4,619,287 99.9%Passed (calculated)—

Source: VIRIDIAN THERAPEUTICS INC., Form 8-K, filed with the SEC on June 24, 2025 — read the filing on EDGAR.

How asset managers voted at the VIRIDIAN THERAPEUTICS INC. 2024-2025 meeting

203 asset managers disclosed a vote on at least one VIRIDIAN THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Chris Cain, Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 68,841,891WITHHELD: 3,200,341
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Chris Cain, Ph.D.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Chris Cain, Ph.D.”): 68,841,891 for, 3,200,341 withheld, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,261,0490 00For
Vanguard4,462,9940 00For
BlackRock1,711,9510 00For
T. Rowe Price1,575,7280 00For
AllianceBernstein1,058,9770 00For
State Street893,2300 0468For
Loomis Sayles00 0784,032Withhold
Charles Schwab00 0581,864Withhold
Victory Capital500,8140 00For
Bridge Builder Trust272,9510 00For
Brighthouse93,0060 0143,344Mixed
Brinker Capital Destinations Trust230,4610 00For
Principal212,6690 00For
Equitable202,3800 00For
DRIEHAUS MUTUAL FUNDS185,5490 00For
TIAA182,9180 00For
JPMorgan170,5520 00For
OPTIMUM FUND TRUST131,5780 00For
QUANTITATIVE MASTER SERIES LLC128,3580 00For
American Century122,7260 00For
CARILLON SERIES TRUST88,3260 00For
AIG/SunAmerica78,3900 00For
Russell Investments00 076,504Withhold
ALPS ETF Trust61,4780 00For
Lincoln Financial54,6000 00For

Fund voting reports, all 59 managers: 25,087,070 for, 1,722,863 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Yiheng Capital Management, L.P.278,7860 00For

Institutional-manager reports, all 1 managers: 278,786 for.

Elect Director: Jeff Ajer

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 71,946,644WITHHELD: 95,588
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jeff Ajer

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeff Ajer”): 71,946,644 for, 95,588 withheld, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,261,0490 00For
Vanguard4,462,9940 00For
BlackRock1,711,9510 00For
T. Rowe Price1,575,7280 00For
AllianceBernstein1,058,9770 00For
State Street893,6980 00For
Loomis Sayles784,0320 00For
Charles Schwab581,8640 00For
Victory Capital500,8140 00For
Bridge Builder Trust272,9510 00For
Brighthouse236,3500 00For
Brinker Capital Destinations Trust230,4610 00For
Principal212,6690 00For
Equitable202,3800 00For
DRIEHAUS MUTUAL FUNDS185,5490 00For
TIAA182,9180 00For
JPMorgan170,5520 00For
OPTIMUM FUND TRUST131,5780 00For
QUANTITATIVE MASTER SERIES LLC128,3580 00For
American Century122,7260 00For
CARILLON SERIES TRUST88,3260 00For
AIG/SunAmerica78,3900 00For
Russell Investments76,5040 00For
ALPS ETF Trust61,4780 00For
Lincoln Financial54,6000 00For

Fund voting reports, all 59 managers: 26,793,269 for, 16,664 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Yiheng Capital Management, L.P.278,7860 00For

Institutional-manager reports, all 1 managers: 278,786 for.

Elect Director: Sarah Gheuens, M.D., Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 55,346,802WITHHELD: 16,695,430
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Sarah Gheuens, M.D., Ph.D.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sarah Gheuens, M.D., Ph.D.”): 55,346,802 for, 16,695,430 withheld, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,261,0490 00For
Vanguard4,462,9940 00For
BlackRock1,711,9510 00For
T. Rowe Price1,575,7280 00For
AllianceBernstein1,058,9770 00For
State Street2,5470 0891,151Withhold
Loomis Sayles784,0320 00For
Charles Schwab581,8640 00For
Victory Capital00 0500,814Withhold
Bridge Builder Trust19,6210 0253,330Mixed
Brighthouse211,4110 024,939Mixed
Brinker Capital Destinations Trust00 0230,461Withhold
Principal212,6690 00For
Equitable202,3800 00For
DRIEHAUS MUTUAL FUNDS00 0185,549Withhold
TIAA182,9180 00For
JPMorgan170,5520 00For
OPTIMUM FUND TRUST00 0131,578Withhold
QUANTITATIVE MASTER SERIES LLC128,3580 00For
American Century00 0122,726Withhold
CARILLON SERIES TRUST00 088,326Withhold
AIG/SunAmerica00 078,390Withhold
Russell Investments76,5040 00For
ALPS ETF Trust00 061,478Withhold
Lincoln Financial00 054,600Withhold

Fund voting reports, all 59 managers: 23,923,027 for, 2,886,906 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Yiheng Capital Management, L.P.278,7860 00For

Institutional-manager reports, all 1 managers: 278,786 for.

Approval of the Viridian Therapeutics, Inc

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 72,005,896AGAINST: 25,668
Details: description as filed, official tally, votes by 62 asset managers

Description as filed by funds: TO APPROVE THE VIRIDIAN THERAPEUTICS, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“5. Approval of the Viridian Therapeutics, Inc”): 72,005,896 for, 25,668 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “TO APPROVE THE VIRIDIAN THERAPEUTICS, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN.” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,261,0490 00For
Vanguard4,462,9940 00For
BlackRock1,711,9510 00For
T. Rowe Price1,575,7280 00For
AllianceBernstein1,058,9770 00For
State Street893,6980 00For
Loomis Sayles784,0320 00For
Charles Schwab581,8640 00For
Victory Capital500,8140 00For
Bridge Builder Trust272,9510 00For
Brighthouse236,3500 00For
Brinker Capital Destinations Trust230,4610 00For
Principal212,6690 00For
Equitable202,3800 00For
DRIEHAUS MUTUAL FUNDS185,5490 00For
TIAA182,9180 00For
JPMorgan170,5520 00For
OPTIMUM FUND TRUST131,5780 00For
QUANTITATIVE MASTER SERIES LLC128,3580 00For
American Century122,7260 00For
CARILLON SERIES TRUST88,3260 00For
AIG/SunAmerica78,3900 00For
Russell Investments76,5040 00For
ALPS ETF Trust61,4780 00For
Lincoln Financial54,6000 00For

Fund voting reports, all 58 managers: 26,793,213 for, 16,664 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “TO APPROVE THE VIRIDIAN THERAPEUTICS, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN.” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Kynam Capital Management, LP3,477,4280 00For
Yiheng Capital Management, L.P.278,7860 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC3,6600 00For

Institutional-manager reports, all 3 managers: 3,759,874 for.

Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

50.2% Majority: yes · of votes cast

FOR 50.2%AGAINST
FOR: 35,322,725AGAINST: 35,076,902

Prior year: 57.0% for (June 17, 2024 meeting) ▼ 6.8 pts

Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 shares.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“4. Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 shares”): 35,322,725 for, 35,076,902 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 50.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of VIRIDIAN THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (2 managers, 56 against, 1,586,421 abstained).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Pla” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity23,88712,237,162 00Against
Vanguard4,462,9940 00For
BlackRock1,711,9510 00For
T. Rowe Price01,575,728 00Against
AllianceBernstein01,058,977 00Against
State Street2,547891,151 00Against
Loomis Sayles784,0320 00For
Charles Schwab581,8640 00For
Victory Capital0500,814 00Against
Bridge Builder Trust19,621253,330 00Mixed
Brighthouse180,41155,939 00Mixed
Brinker Capital Destinations Trust0230,461 00Against
Principal159212,510 00Against
Equitable133,11069,270 00Mixed
DRIEHAUS MUTUAL FUNDS0185,549 00Against
TIAA0182,918 00Against
JPMorgan170,5520 00For
OPTIMUM FUND TRUST0131,578 00Against
QUANTITATIVE MASTER SERIES LLC128,3580 00For
American Century0122,726 00Against
CARILLON SERIES TRUST088,326 00Against
AIG/SunAmerica078,390 00Against
Russell Investments76,5040 00For
ALPS ETF Trust061,478 00Against
Lincoln Financial054,600 00Against

Fund voting reports, all 58 managers: 8,441,337 for, 18,351,876 against, 16,664 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Pla” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Kynam Capital Management, LP3,477,4280 00For
Yiheng Capital Management, L.P.278,7860 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC03,660 00Against

Institutional-manager reports, all 3 managers: 3,756,214 for, 3,660 against.

Approval, on an advisory basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 6 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST
FOR: 56,046,366AGAINST: 15,957,526

Prior year: 58.0% for (June 17, 2024 meeting) ▲ 19.8 pts

Details: description as filed, official tally, votes by 203 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 56,046,366 for, 15,957,526 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,261,0490 00For
Vanguard4,462,9940 00For
BlackRock1,711,9510 00For
T. Rowe Price1,575,7280 00For
AllianceBernstein01,058,977 00Against
State Street892,5721,126 00For
Loomis Sayles784,0320 00For
Charles Schwab581,8640 00For
Victory Capital0500,814 00Against
Bridge Builder Trust19,621253,330 00Mixed
Brighthouse211,41124,939 00Mixed
Brinker Capital Destinations Trust2,054228,407 00Against
Principal159212,510 00Against
Equitable136,91065,470 00Mixed
DRIEHAUS MUTUAL FUNDS0185,549 00Against
TIAA182,9180 00For
JPMorgan170,5520 00For
OPTIMUM FUND TRUST0131,578 00Against
QUANTITATIVE MASTER SERIES LLC128,3580 00For
American Century0122,726 00Against
CARILLON SERIES TRUST088,326 00Against
AIG/SunAmerica078,390 00Against
Russell Investments76,5040 00For
ALPS ETF Trust061,478 00Against
Lincoln Financial54,6000 00For

Fund voting reports, all 59 managers: 23,516,832 for, 3,276,437 against, 16,664 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 161 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,007,6530 00For
Commodore Capital LP05,250,000 00Against
VR Adviser, LLC3,882,7090 00For
Kynam Capital Management, LP3,477,4280 00For
Fairmount Funds Management LLC3,445,8130 00For
Deep Track Capital, LP2,526,6620 00For
Novo Holdings A/S2,327,6400 00For
State Street2,269,31930,828 00For
Paradigm Biocapital Advisors LP02,095,079 00Against
T. Rowe Price2,093,5160 00For
BlackRock2,005,9706,709 00For
GEODE CAPITAL MANAGEMENT, LLC1,726,1920 00For
AllianceBernstein01,720,180 00Against
MAVERICK CAPITAL LTD1,698,6730 00For
Eversept Partners, LP1,586,4210 00For
Loomis Sayles1,243,20091,496 00Mixed
PICTET ASSET MANAGEMENT SA01,128,441 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.01,114,586 00Against
Vivo Capital, LLC982,5760 00For
Woodline Partners LP813,3760 00For
Victory Capital0811,714 00Against
5AM Venture Management, LLC736,5950 00For
Charles Schwab598,9520 00For
Fisher Asset Management, LLC0383,070 00Against
Northern Trust371,2635,349 00For

Institutional-manager reports, all 161 managers: 46,731,041 for, 14,692,298 against, 4,452 abstained, 680 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal…

Calculated outcomeFund totals may overlapAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 76,059,006AGAINST: 577,139

Prior year: 100.0% for (June 17, 2024 meeting) ▼ 0.7 pts

Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 76,059,006 for, 577,139 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEA” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity12,261,0490 00For
Vanguard4,462,9940 00For
BlackRock1,711,9510 00For
T. Rowe Price1,575,7280 00For
AllianceBernstein1,058,9770 00For
State Street893,64652 00For
Loomis Sayles784,0320 00For
Charles Schwab581,8640 00For
Victory Capital500,8140 00For
Bridge Builder Trust272,9510 00For
Brighthouse236,3500 00For
Brinker Capital Destinations Trust230,4610 00For
Principal212,6690 00For
Equitable202,3800 00For
DRIEHAUS MUTUAL FUNDS185,5490 00For
TIAA182,9180 00For
JPMorgan170,5520 00For
OPTIMUM FUND TRUST131,5780 00For
QUANTITATIVE MASTER SERIES LLC128,3580 00For
American Century122,7260 00For
CARILLON SERIES TRUST88,3260 00For
AIG/SunAmerica78,3900 00For
Russell Investments76,5040 00For
ALPS ETF Trust61,4780 00For
Lincoln Financial54,6000 00For

Fund voting reports, all 59 managers: 26,793,217 for, 52 against, 16,664 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEA” at VIRIDIAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Yiheng Capital Management, L.P.278,7860 00For

Institutional-manager reports, all 1 managers: 278,786 for.

Largest VIRIDIAN THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 81,589,427 shares outstanding at the time of that meeting.

Fund voting reports: top VIRIDIAN THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 15.03%
2Vanguard 5.47%
3BlackRock 2.10%
4T. Rowe Price 1.93%
5AllianceBernstein 1.30%
6State Street 1.10%
7Loomis Sayles 0.96%
8Charles Schwab 0.71%
9Victory Capital 0.61%
10Bridge Builder Trust 0.33%
Institutional-manager reports: top VIRIDIAN THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 14.72%
2Commodore Capital LP 6.43%
3VR Adviser, LLC 4.76%
4Kynam Capital Management, LP 4.26%
5Fairmount Funds Management LLC 4.22%
6Deep Track Capital, LP 3.10%
7Novo Holdings A/S 2.85%
8State Street 2.82%
9Paradigm Biocapital Advisors LP 2.57%
10T. Rowe Price 2.57%

Reported VIRIDIAN THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

VIRIDIAN THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Fairmount Funds Management LLC17,201,800 —Schedule 13D, filed May 13, 2026
Entities affiliated with Fairmount Funds Management LLC15,556,685 —Proxy statement (DEF 14A), proxy filed April 25, 2025
FMR (Fidelity)12,222,986 —Form 13F, quarter ended March 31, 2025
Entities affiliated with FMR LLC7,625,542 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Bellevue Group AG6,726,144 —Schedule 13G, filed May 15, 2026
BlackRock5,708,110 —Form 13F, quarter ended March 31, 2025
Paradigm BioCapital Advisors LP5,633,788 —Schedule 13G, filed June 26, 2026
Deep Track Capital, LP5,417,660 —Schedule 13G, filed May 8, 2026
Entities affiliated with Deep Track Capital, LP5,378,997 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Vanguard Group4,563,100 —Form 13F, quarter ended March 31, 2025

Percentages above are of 81,589,427 shares outstanding, as reported by VIRIDIAN THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At VIRIDIAN THERAPEUTICS INC.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 203 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 1,563 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 78% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VIRIDIAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIRIDIAN THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

VIRIDIAN THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “VIRIDIAN THERAPEUTICS (VRDN) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/viridian-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.